ORYZON to provide corporate progress updates at several events in January

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give an update on corporate progress at several international events in January.

Oryzon will participate at the 7th Sachs Annual Neuroscience Innovation Forum, which will be held on January 7 at the Marine’s Memorial Club in San Francisco (USA). The company will take part in a panel entitled “New Approaches to Neuro Psychiatric Disorders Panel” at 1:00 pm PST and will provide a corporate update on its CNS program at 3:30 pm PST. Click on link for more info about 7th Sachs Annual Neuroscience Innovation Forum.

Oryzon will participate at the 13th Annual LifeSci Advisors Corporate Access Event, which will be held at the Beacon Grand Hotel in San Francisco (USA) on January 8-10, where the company will provide a corporate update to investors and will maintain a set of meetings with pharma companies. Click on link for more info about the 13th Annual LifeSci Advisors Corporate Access Event.

Oryzon will participate at the Biotech Showcase 2024 Event, which will take place at the Hilton Union Square hotel in San Francisco (USA) on January 8-10. Oryzon will provide a corporate update on January 9 at 2:30 pm PST and maintain a set of meetings with pharma companies. Click on link for more info about the Biotech Showcase 2024.

Oryzon has been invited to participate at the 42nd Annual J.P. Morgan Healthcare Conference, which will be held on January 8-11 at the Westin St. Francis Hotel in San Francisco (USA). Click on link for more info about the Annual JP Morgan Healthcare conference.

Oryzon will also attend the Invest Securities Biomed Forum 2024, which will be held in Paris (France) on January 30.